S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
S&P 500   3,003.80 (-0.10%)
DOW   26,865.18 (+0.14%)
QQQ   192.41 (-0.51%)
AAPL   240.85 (+0.14%)
MSFT   136.93 (-1.08%)
GOOGL   1,241.08 (-0.26%)
AMZN   1,766.27 (-1.09%)
CGC   21.01 (+3.24%)
NVDA   196.61 (+0.30%)
BABA   169.58 (-2.27%)
TSLA   256.55 (+1.20%)
AMD   31.56 (-1.47%)
T   38.28 (+0.13%)
F   9.06 (+0.33%)
ACB   3.59 (-2.71%)
PRI   126.15 (+0.37%)
NFLX   267.61 (-3.75%)
GILD   66.03 (+1.26%)
DIS   132.97 (+2.08%)
Log in

Neurotrope Stock Price, News & Analysis (NASDAQ:NTRP)

$0.64
-0.02 (-3.03 %)
(As of 10/22/2019 03:30 PM ET)
Today's Range
$0.64
Now: $0.64
$0.71
50-Day Range
$0.64
MA: $1.42
$5.31
52-Week Range
$0.63
Now: $0.64
$8.40
Volume10,008 shs
Average Volume826,833 shs
Market Capitalization$8.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.05 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees6
Market Cap$8.33 million
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.


Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) announced its earnings results on Thursday, August, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.07. View Neurotrope's Earnings History.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Neurotrope.

What price target have analysts set for NTRP?

2 brokerages have issued twelve-month price objectives for Neurotrope's shares. Their predictions range from $1.00 to $16.00. On average, they anticipate Neurotrope's stock price to reach $8.50 in the next year. This suggests a possible upside of 1,228.1% from the stock's current price. View Analyst Price Targets for Neurotrope.

What is the consensus analysts' recommendation for Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

What are Wall Street analysts saying about Neurotrope stock?

Here are some recent quotes from research analysts about Neurotrope stock:
  • 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (10/10/2019)
  • 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)

Has Neurotrope been receiving favorable news coverage?

News stories about NTRP stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurotrope earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Neurotrope.

Are investors shorting Neurotrope?

Neurotrope saw a decrease in short interest in September. As of September 30th, there was short interest totalling 236,300 shares, a decrease of 57.6% from the August 30th total of 557,100 shares. Based on an average daily trading volume, of 508,700 shares, the short-interest ratio is presently 0.5 days. Currently, 2.4% of the shares of the stock are short sold. View Neurotrope's Current Options Chain.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Canopy Growth (CGC), Intel (INTC), JD.Com (JD), Iovance Biotherapeutics (IOVA), Pieris Pharmaceuticals (PIRS) and Baidu (BIDU).

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $0.64.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $8.33 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

What is Neurotrope's official website?

The official website for Neurotrope is http://www.neurotropebioscience.com/.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]


MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel